SML4212
JQKD82 dihydrochloride
≥98% (HPLC), powder, Histone Demethylase Inhibitor
别名:
2,4-Bis(1-methylethoxy)phenyl 2-[[[2-[[2-(dimethylamino)ethyl]ethylamino]-2-oxoethyl]amino]methyl]-4-pyridinecarboxylate dihydrochloride, JQKD 82 dihydrochloride, JQKD-82 dihydrochloride
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to beige
溶解性
H2O: 2 mg/mL, clear
储存温度
-10 to -25°C
SMILES字符串
O=C(C1=CC(CNCC(N(CCN(C)C)CC)=O)=NC=C1)OC2=CC=C(C=C2OC(C)C)OC(C)C.Cl.Cl
一般描述
JQKD82 dihydrochloride is histone H3K4 demethylase inhibitor is a produg of KDM5-C49 phenol ester prodrug that selectively upregulates H3K4me3 and inhibits KDM5-dependent cancer growth.
(KDOAM-21; KDM5A/B/C/D Ki = 2/1/6.1/3.4 nM vs. KDM4C/6B/3A/2A Ki =0.51/4.55/2.59/4.4 μM; KDM5A/B/C/D IC50 = 1.1/0.8/3.2/2.7 μM by FDH assay with[αKG] = 1 mM & [E]/[S] = 0.5/15 μM; KDM5A/B/C IC50 = 25/30/59 nM by alphaLISA with [αKG] = 25 μM & [E]/[S] = 10/100 nM). JQKD82 selectively upregulates cellular histone H3K4me3 with a higher efficacy than KDM5-C49 orKDM5-C70 (3 μM for 24 h; MM.1S cells), and inhibits myeloma growth in cultures (MM.1S IC50 = 0.42 μM vs IC50 3.1 μM/KDM5-C70, >10 μM/KDM5-C49) and in vivo (50 mg/kg b.i.d. i.p. to mice with MOLP-8 xenograft).
(KDOAM-21; KDM5A/B/C/D Ki = 2/1/6.1/3.4 nM vs. KDM4C/6B/3A/2A Ki =0.51/4.55/2.59/4.4 μM; KDM5A/B/C/D IC50 = 1.1/0.8/3.2/2.7 μM by FDH assay with[αKG] = 1 mM & [E]/[S] = 0.5/15 μM; KDM5A/B/C IC50 = 25/30/59 nM by alphaLISA with [αKG] = 25 μM & [E]/[S] = 10/100 nM). JQKD82 selectively upregulates cellular histone H3K4me3 with a higher efficacy than KDM5-C49 orKDM5-C70 (3 μM for 24 h; MM.1S cells), and inhibits myeloma growth in cultures (MM.1S IC50 = 0.42 μM vs IC50 3.1 μM/KDM5-C70, >10 μM/KDM5-C49) and in vivo (50 mg/kg b.i.d. i.p. to mice with MOLP-8 xenograft).
应用
JQKD82 dihydrochloride may be used:
- to study its effects on lysine demethylase 5A (KDM5A) function in multiple myeloma research
- as a potential agent in HIV-1 research, where it was evaluated for its ability to reactivate latent HIV-1 inT cells
- to study its effects on cell cycle arrest and apoptosis induction
生化/生理作用
A selective and cell-permeable lysine demethylase 5(KDM5) inhibitor.
免责声明
Hygroscopic
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Tai-Wei Li et al.
Antiviral research, 228, 105947-105947 (2024-06-27)
Combinational antiretroviral therapy (cART) suppresses human immunodeficiency virus type 1 (HIV-1) viral replication and pathogenesis in acquired immunodeficiency syndrome (AIDS) patients. However, HIV-1 remains in the latent stage of infection by suppressing viral transcription, which hinders an HIV-1 cure. One
Rashmi Srivastava et al.
Epigenomes, 7(2) (2023-05-23)
Epigenetic modifications are heritable, reversible changes in histones or the DNA that control gene functions, being exogenous to the genomic sequence itself. Human diseases, particularly cancer, are frequently connected to epigenetic dysregulations. One of them is histone methylation, which is
Hiroto Ohguchi et al.
Blood cancer discovery, 2(4), 370-387 (2021-07-15)
Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3K4 trimethylation, a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC targeted genes in multiple
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持